Rosalyn Singleton1, Sara Rutz, Gretchen Day, Melissa Hammes, Amy Swango Wilson, Mary Herrick, Connie Mazut, Laura Brunner, Jennifer Prince, Christine Desnoyers, Jennifer Shaw, Matthew Hirschfeld, Heather Palis, Amanda Slaunwhite. 1. Alaska Native Tribal Health Consortium, Anchorage, AK (RS, GD, SW, CM); University of Washington, School of Medicine, Alaska WWAMI, Anchorage, AK (SR); Southcentral Foundation, Anchorage, AK (MH, MH, JS, MH); Fairbanks Memorial Hospital, Fairbanks, AK (LB); Yukon Kuskokwim Health Corporation, Bethel, AK (JP); Yukon Kuskokwim Health Corporation, Bethel, Alaska (CD); Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada (HP); British Columbia Centre for Disease Control, Vancouver, BC, Canada (HP, AS); School of Population and Public Health, University of British Columbia, Vancouver, BC, Canada (AS).
Abstract
OBJECTIVES: The number of women with opioid-related diagnoses in the United States has significantly increased in recent decades, resulting in concomitantly higher rates of infants born with neonatal opioid withdrawal syndrome (NOWS). Addressing prenatal opioid exposure is a priority for Alaska health systems. The objectives of this study were to: (1) identify maternal and neonatal factors associated with receipt of Medication for opioid use disorder (MOUD) and (2) determine the impact of prenatal MOUD on discharge to parents among infants with NOWS in 3 Alaska hospitals. METHODS: A retrospective chart review using a standard abstraction form was conducted to collect data on neonatal and maternal characteristics, neonatal treatment, and infant discharge disposition for infants with NOWS born at the 3 hospitals between July 2016 and December 2019. A multivariable logistic regression model was used to determine factors associated with discharge to parents. RESULTS: There were 10,719 births at the 3 hospitals during the study period, including 193 infants (1.8%) with NOWS. Among the 193 mothers, 91 (47.2%) received MOUD during pregnancy. Among infants with NOWS, 136 (70.5%) were discharged to parents, 51 (26.4%) were discharged to a relative or foster care. Infants were significantly (odds ratio 3.9) more likely to be discharged to parents if the mother had received prenatal MOUD. CONCLUSIONS: MOUD among pregnant women with opioid use disorder furthers the goal of keeping families together and is a critical step towards reducing the impact of the ongoing opioid epidemic on Alaska families, communities, and the child welfare system.
OBJECTIVES: The number of women with opioid-related diagnoses in the United States has significantly increased in recent decades, resulting in concomitantly higher rates of infants born with neonatal opioid withdrawal syndrome (NOWS). Addressing prenatal opioid exposure is a priority for Alaska health systems. The objectives of this study were to: (1) identify maternal and neonatal factors associated with receipt of Medication for opioid use disorder (MOUD) and (2) determine the impact of prenatal MOUD on discharge to parents among infants with NOWS in 3 Alaska hospitals. METHODS: A retrospective chart review using a standard abstraction form was conducted to collect data on neonatal and maternal characteristics, neonatal treatment, and infant discharge disposition for infants with NOWS born at the 3 hospitals between July 2016 and December 2019. A multivariable logistic regression model was used to determine factors associated with discharge to parents. RESULTS: There were 10,719 births at the 3 hospitals during the study period, including 193 infants (1.8%) with NOWS. Among the 193 mothers, 91 (47.2%) received MOUD during pregnancy. Among infants with NOWS, 136 (70.5%) were discharged to parents, 51 (26.4%) were discharged to a relative or foster care. Infants were significantly (odds ratio 3.9) more likely to be discharged to parents if the mother had received prenatal MOUD. CONCLUSIONS: MOUD among pregnant women with opioid use disorder furthers the goal of keeping families together and is a critical step towards reducing the impact of the ongoing opioid epidemic on Alaska families, communities, and the child welfare system.
Authors: Hendrée E Jones; Krisanna Deppen; Mark L Hudak; Lisa Leffert; Carol McClelland; Leyla Sahin; Jacquelyn Starer; Mishka Terplan; John M Thorp; James Walsh; Andreea A Creanga Journal: Am J Obstet Gynecol Date: 2013-10-10 Impact factor: 8.661
Authors: Jessica N Snowden; A Akshatha; Robert D Annett; Margaret M Crawford; Abhik Das; Lori A Devlin; Rosemary D Higgins; Zhuopei Hu; Elizabeth Lindsay; Stephanie Merhar; Clare Campbell Nesmith; Heather Pratt-Chavez; Judith Ross; Alan E Simon; M Cody Smith; Christine B Turley; Anita Walden; Leslie Young; Bonny Whalen Journal: Hosp Pediatr Date: 2019-07-19
Authors: Rosalyn Singleton; Amanda Slaunwhite; Mary Herrick; Matthew Hirschfeld; Laura Brunner; Christine Hallas; Sarah Truit; Sally Hanson; Margaret Young; Evelyn Rider Journal: Int J Circumpolar Health Date: 2019-12 Impact factor: 1.228
Authors: Leslie W Young; Zhuopei Hu; Robert D Annett; Abhik Das; Janell F Fuller; Rosemary D Higgins; Barry M Lester; Stephanie L Merhar; Alan E Simon; Songthip Ounpraseuth; P Brian Smith; Margaret M Crawford; Andrew M Atz; Lesley E Cottrell; Adam J Czynski; Sarah Newman; David A Paul; Pablo J Sánchez; Erin O Semmens; M Cody Smith; Christine B Turley; Bonny L Whalen; Brenda B Poindexter; Jessica N Snowden; Lori A Devlin Journal: Pediatrics Date: 2020-12-21 Impact factor: 7.124
Authors: Jerreed D Ivanich; Julia Weckstein; Paul S Nestadt; Mary F Cwik; Melissa Walls; Emily E Haroz; Victoria M O'Keefe; Novalene Goklish; Allison Barlow Journal: Am J Drug Alcohol Abuse Date: 2021-08-10 Impact factor: 3.912